Antiangiogenic Agents in Cancer Therapy

Description

Front Matter....Pages i-xi Front Matter....Pages 1-1 Angiogenesis and Oxygen Transport in Solid Tumors....Pages 3-21 Oxygenation of Solid Tumors in Animals and Patients....Pages 23-35 Role of Inflammatory Mediators in Angiogenesis....Pages 37-50 Intra- and Extracellular pH in Solid Tumors....Pages 51-64 Contribution of the Extracellular Matrix and Macrophages in Angiogenesis....Pages 65-75 Regulation of Angiogenesis by the Organ Microenvironment....Pages 77-91 Fibroblast Growth Factors in Tumor Progression and Angiogenesis....Pages 93-118 Role of Vascular Endothelial Growth Factor in Regulation of Angiogenesis....Pages 119-141 Regulatory Aspects of Neovascularization....Pages 143-150 Front Matter....Pages 151-151 Squalamine....Pages 153-174 Cartilage as a Source of Natural Inhibitors of Angiogenesis....Pages 175-183 Thrombospondin as an Inhibitor of Angiogenesis....Pages 185-203 Matrix Metalloproteinase Inhibitors....Pages 205-223 Angiostatin Protein and Other Plasminogen Fragments....Pages 225-236 Dietary and Nutritional Modulation of Tumor Angiogenesis....Pages 237-261 Thalidomide and Analogs....Pages 263-274 Front Matter....Pages 275-275 Potentiation of Cytotoxic Cancer Therapies by Antiangiogenic Agents....Pages 277-316 Prognostic Significance of Tumor Vascularity....Pages 317-339 Endpoints for Determination of Efficacy of Antiangiogenic Agents in Clinical Trials....Pages 341-353 Retinoids and Interferons as Antiangiogenic Cancer Drugs....Pages 355-370 Front Matter....Pages 275-275 Pentosan Polysulfate....Pages 371-383 TNP-470....Pages 385-398 Batimastat and Marimastat in Cancer....Pages 399-405 Thalidomide....Pages 407-422 Ribozyme Targeting of Angiogenic Molecules....Pages 423-441 Back Matter....Pages 443-450